

1

2 **The effect of postoperative continuation of antibiotic prophylaxis on the**
3 **incidence of surgical site infection: a systematic review and meta-analysis.**

4 Stijn de Jonge^{1*}, Quirine Boldingh^{1*}, Joseph Solomkin², Patchen Dellinger³, Matthias Egger⁴, Georgia
5 Salanti⁴, Benedetta Allegranzi⁵, Marja Boermeester¹

6

7 1. Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands (S de Jonge MD,
8 Q Boldingh MD, Prof M Boermeester MD)

9 2. Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA (Prof
10 Emeritus J Solomkin MD)

11 3. Department of Surgery, University of Washington Medical Center, Seattle, Washington, USA (Prof
12 Emeritus E P Dellinger)

13 4. Institute for Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland (Prof M
14 Egger MD, Prof G Salanti PhD)

15 5. WHO Infection Prevention and Control Global Unit, Service Delivery and Safety, Geneva,
16 Switzerland (B Allegranzi MD)

17

18 * These authors contributed equally.

19

20 Corresponding Author: Prof. M.A. Boermeester, Academic Medical Center, PO Box 22660,

21 Amsterdam 1100 DD, the Netherlands, e-mail: m.a.boermeester@amc.uva.nl, telephone number 0031

22 (0)20 566 2766.

23

24 Role of funding source: No funding was received.

25

26 Category: systematic review

27

28 **Summary**

29 **Background:** Surgical antibiotic prophylaxis (SAP) is frequently continued for one or more days after
30 surgery to prevent surgical site infection (SSI). Continuing SAP after the operation may have no
31 advantage compared to immediate discontinuation and unnecessarily expose patients to risks associated
32 with antibiotic use. In 2016, the World Health Organization (WHO) recommended discontinuation of
33 SAP. We aim to update the evidence that formed the basis for this recommendation.

34
35 **Methods:** For this systematic review and meta-analysis we searched MEDLINE, Embase, CINAHL,
36 CENTRAL, and WHO regional medical databases from Jan 1990 to August 2018 for randomised
37 controlled trials (RCT) comparing the effect of postoperative SAP continuation to its discontinuation.
38 We excluded, amongst others, studies that did not administer the first dose preoperatively by
39 intravenous infusion. A protocol for this review was registered with at PROSPERO:
40 http://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42017060829.

41
42 **Findings:** We identified 83 relevant RCTs. The main meta-analysis included 52 RCTs with 19,273
43 participants. The combined relative risk of SSI comparing postoperative SAP continuation with
44 discontinuation was 0.89 (95% confidence interval: 0.79-1.00; tau²: 0.001. Pre-specified subgroup
45 analyses and meta-regression showed a significant association between the effect estimate and best
46 practice standards of SAP, defined by the American Society of Health-System Pharmacists guidelines,
47 involving timing and intraoperative repetition (Subgroup: P = 0.048, variance explained: 100%). There
48 was evidence of effect in trials that did not meet best practice standards of SAP regarding timing and
49 intraoperative repetition (RR: 0.79; 95%CI: 0.67-0.94 RR, tau² = 0.019), but not in trials that did (RR:
50 1.04; 95%CI: 0.85-1.27, tau² = 0.00).

51
52 **Interpretation:** Overall there is no strong evidence for a benefit of postoperative continuation of SAP.
53 When SAP best practice standards were followed, post-operative SAP continuation did not yield any
54 additional benefit in reduction of SSI. These findings support WHO recommendations against this
55 practice.

56
57 **Funding:** None
58

59 **Panel: Research in context**

60 **Evidence before this study**

61 Antibiotics should be used judiciously and according to the evidence due to concerns about the
62 emergence of antimicrobial resistance and other hazardous side effects. One in seven in-hospital
63 prescriptions for antibiotics is for surgical antibiotic prophylaxis (SAP) and is frequently continued for
64 several days after surgery. While the effectiveness of appropriate SAP to prevent surgical site
65 infections (SSI) in indicated procedures is well established, an increasing body of evidence suggests
66 that a single preoperative dose of SAP with intraoperative repeat of administration when indicated may
67 be as effective as a prolonged postoperative regimen. Longer exposure to antibiotics has been
68 associated with an increased risk of antimicrobial resistance, *Clostridium difficile* infection and acute
69 kidney injury. Across surgical subspecialties, many randomised controlled trials (RCTs) and some
70 systematic reviews exist. No systematic review considers all the available evidence. In 2015, the World
71 Health Organization (WHO) conducted a systematic review and meta-analysis and based on the results
72 strongly recommended against postoperative continuation of SAP, but only a summary of the review
73 was published. A recent European multi-country study found that SAP is still routinely continued up to
74 several days after surgery. Additional trials became available after publication of the guidelines, and
75 some of the data included in the original WHO review may no longer be representative for current best
76 practice standards of SAP.

77
78 **Added value of this study**

79 We searched MEDLINE, Embase, CINAHL, CENTRAL, and WHO regional medical databases from
80 Jan 1990 to August 2018 for studies investigating the effect of postoperative continuation of
81 preoperative SAP compared to postoperative discontinuation, in patients undergoing any surgical
82 procedures with SAP indication, on the incidence of SSI. This systematic review of 83 RCTs, of which
83 52 RCTs were included in the main meta-analysis, provides a comprehensive overview of all the
84 available evidence on the practice of postoperative continuation of SAP across surgical subspecialties.
85 We found no conclusive evidence that patients benefit from continued SAP after surgery based on
86 moderate quality of evidence. Pre-specified subgroup analysis indicated that postoperatively continued
87 SAP is only effective when preoperative SAP is not timed adequately and not repeated according to the
88 duration of the procedure. In contrast, when SAP best practices standards on timing and intra-operative
89 repetition were applied, no effect of postoperative SAP continuation in reducing SSI risk was found.

90
91 **Implications of all the available evidence**

92 In this systematic review and meta-analysis, no conclusive evidence for a benefit of postoperative
93 continuation of SAP as compared to postoperative discontinuation for the reduction of SSI was found.
94 When SAP best practices were followed, post-operative SAP continuation did not yield any additional
95 benefit in reduction of SSI. Considering the possible adverse effects, there is no basis for postoperative
96 continuation of SAP. Increased awareness and education about best practices are warranted for both
97 patients and practitioners and need to be the basis of stewardship efforts among surgeons. Future
98 research to further clarify effectiveness of SAP continuation, if any, should include monitoring of pre-
99 specified adverse events and standardize preoperative timing and intraoperative dose repetition
100 according to evidence-based standardized criteria.

101 Introduction

102 Antibiotic use is under scrutiny due to concerns about the emergence of antimicrobial resistance and
103 other hazardous side effects.^{1,2} One in seven in-hospital prescriptions for antibiotics is for surgical
104 antibiotic prophylaxis (SAP) and is frequently continued for several days after surgery.³ While the
105 effectiveness of appropriate SAP to prevent surgical site infections (SSI) in indicated procedures is
106 well established,⁴ an increasing body of evidence suggests that a single preoperative dose of SAP, with
107 intraoperative repeat of administration when indicated, may be as effective as a prolonged
108 postoperative regimen in a variety of procedures.^{5,6} Longer exposure to antibiotics has been associated
109 with an increased risk of antimicrobial resistance, *clostridium difficile* infection and acute kidney
110 injury,⁷⁻⁹ while avoiding postoperative continuation of antibiotic prophylaxis has been associated with
111 reduced risk of *clostridium difficile* infection.¹⁰ Based on a systematic review and meta-analyses that
112 included a wide range of surgical subspecialties, the World Health Organization (WHO) strongly
113 recommended against postoperative continuation of SAP in the 2016 global guidelines for SSI
114 prevention.¹¹ The Centers for Disease Control and prevention (CDC), the National Institute for Health
115 and Care excellence (NICE) and other organizations made similar recommendations.^{4,12,13} Despite this,
116 SAP continuation is still very common across the world.¹⁴ A recent global point prevalence study
117 revealed that the percentage of patients that receive SAP for more than one day ranged from 29,5% in
118 Western Europe to 92,5% in Africa.¹⁴ Lack of utilization monitoring and poor implementation of
119 antimicrobial stewardship programmes may facilitate the continuation of this practice.^{15,16} However,
120 limited awareness of the existing evidence or new potentially contradicting evidence may also
121 contribute. Only a summary of the systematic review conducted for the WHO recommendation was
122 published.¹³ Evidence continues to emerge through publication of new randomized controlled trials,^{17,18}
123 and some of the existing data used in the initial review may no longer be representative for current best
124 practice standards of SAP.⁴ We therefore conducted a systematic literature review and meta-analysis,
125 updating the evidence on which the 2016 WHO recommendation was based, and re-assessed the effect
126 of postoperative continuation of preoperative SAP on the incidence of SSI compared to postoperative
127 discontinuation in patients undergoing surgical procedures.

129 Methods

130 Search strategy and selection criteria

131 The protocol for this systematic review and meta-analysis was registered in the PROSPERO register
132 (see http://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42017060829)¹⁹ and reported
133 according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)
134 statement.²⁰

135 Randomised controlled trials (RCTs) investigating the effect on the incidence of SSI of postoperative
136 continuation of preoperative SAP compared to postoperative discontinuation, in patients undergoing
137 any surgical procedures with an indication for SAP⁴ were eligible. We excluded studies that compared
138 regimens that also differed with regard to dose and agent used, studies that did not administer the first
139 dose preoperatively by intravenous infusion, studies on dirty procedures or established infections
140 where antibiotic use was classified as treatment, and observational and pre-clinical studies. We limited
141 eligibility to studies published from 1990 onwards because infection prevention practices before 1990
142 differed significantly from current practices. We applied no restrictions regarding the definition of
143 outcomes, length of follow up or language.

144 We searched Medline (PubMed); Excerpta Medica Database (EMBASE); Cumulative Index to Nursing
145 and Allied Health Literature (CINAHL); Cochrane Central Register of Controlled Trials (CENTRAL);
146 and WHO regional medical databases from 1990 to August 2018. The search terms used were: surgical
147 wound infection, surgical site infection, SSI, SSIs, surgical wound infection, surgical infection, post-
148 operative wound infection, postoperative wound infection, antibiotic prophylaxis, antimicrobial,
149 antibiotic, prolong, duration, short, long, single dose, multi dose. These terms were combined with the
150 highly sensitive search strategy of Cochrane for identifying RCTs.²¹ The full search strategy is
151 available in the appendix, p 1.

152 Two authors (QB and SW) independently screened the titles and abstracts for eligibility. When title and
153 abstract indicated potential eligibility, the full-text article was obtained. To avoid language bias,
154 articles published in languages other than English were translated by authors proficient in the language
155 or, when unavailable, by an online multilingual machine translation service
156 (<https://translate.google.com>).²² Any disagreements were resolved through discussion or, when
157 necessary, after consultation with the senior author (MB).

159 Data analysis

160 Two authors independently reviewed each eligible article and extracted relevant data using a
161 standardized data extraction form. Data collection covered design, publication date, scope, number of
162 participants, type of surgery, contamination by CDC wound classification,²³ outcome definition, follow
163 up, dosage and regimen of antibiotics in both intervention and control group including timing of the
164 preoperative dose and intraoperative repeat of administration when indicated, results, resource use and
165 adverse events. We contacted all authors by email, or surface mail when email was not available, for
166 detailed information on timing of the first dose, procedure duration, intraoperative repeat of
167 administration, adverse events and the antibiotics used. We collected drug characteristics from the
168 American Society of Health-System Pharmacists (ASHP) clinical practice guidelines for antimicrobial
169 prophylaxis in surgery and a comprehensive database for bioinformatics and cheminformatics
170 (DrugBank Version 5·0 <https://www.drugbank.ca>).^{4,24} When finally insufficient information could be
171 retrieved on timing of the preoperative dose or intraoperative repeat of administration, we assumed this
172 was not standardized during the study.

173 Two authors (QB and SW) independently assessed the risk of bias of included studies using the
174 Cochrane Collaboration's tool for assessing risk of bias in RCTs.²¹ Criteria for risk of bias are listed in
175 the appendix, p 2. Conflicts were resolved through discussion or after consultation with the senior
176 author (MB). Results were displayed in summary figures generated by Review Manager Version 5·3
177 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark; 2008). The
178 possibility of publication bias was visually assessed using a contour enhanced funnel plot.²⁵

179 Trials of any surgical procedure that compared postoperative continuation of SAP of any duration with
180 immediate postoperative discontinuation were included in the main analysis. Further analyses were
181 conducted comparing postoperative regimens of different duration. We calculated summary relative
182 risks (RR) with the corresponding 95% confidence interval (CI) using a random effects model
183 (DerSimonian and Laird), thus taking into account statistical heterogeneity.²⁶ The χ^2 test for
184 heterogeneity was performed, and the ratio of true heterogeneity to total variation in observed effects
185 was expressed using the I^2 statistic. The extent of heterogeneity was evaluated using tau².

186 Current best practice standards of SAP are described in the ASHP clinical practice guidelines for
187 antimicrobial prophylaxis in surgery.⁴ We accounted for these standards in pre-specified subgroup
188 analyses for studies standardizing: 1) timing of the first preoperative dose within 60 minutes prior to
189 incision, 2) redosing when procedure duration exceeded two times the half-life of the antibiotic agent,
190 and 3) adherence to current best practice standards meeting both these conditions. To explore potential
191 procedure specific effects, we performed sub-group analyses by procedure type. For each subgroup
192 analysis, we used random-effects meta-regression to investigate the association of subgroup
193 characteristics with the intervention effect.²⁷ The proportion of variance explained was calculated by
194 examining the change in tau².²⁸

195 Statistical analyses were done in Stata version 15·0 (Stata Corporation, College Station, TX, USA).
196 We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE)
197 methodology to judge the quality of the retrieved evidence (GRADE Pro software,
198 <http://gradepro.org/>).²⁹ Predefined subgroups with a strong association with the intervention effect
199 where graded individually. Optimal information size, defined as the number of participants needed for
200 a single adequately powered trial, was calculated assuming a type-1 error (α) of 0·05, a type 2 error (β)
201 of 0·2 and a relative risk reduction of 0·25.²⁹ If a confidence interval failed to exclude appreciable
202 benefit of SAP continuation, defined as a relative risk reduction of 0·25, the quality of evidence was
203 downgraded regardless of the optimal information size.²⁹

204

205 **Role of the funding source**

206 There was no funding for this study. The corresponding author had full access to all the data in the
207 study and had final responsibility for the decision to submit for publication.

208

209

210

211 **Results**

212 The search retrieved 3,238 potentially relevant records and 24 additional records were identified
213 through other sources. We assessed 147 full-text publications for eligibility; 83 RCTs were critically
214 appraised and included in meta-analyses. The selection procedure is summarised in Figure 1. Reasons
215 for exclusion after full text assessment are described in the appendix, pp 3-4.

216 Study characteristics are listed in the appendix, pp 5-11. In total, 24,434 participants were included in
217 83 RCTs comparing different postoperative SAP regimens with SSI as an outcome. Source countries
218 included Iran, Saudi Arabia, The United States of America, Hong Kong, Japan, Italy, India, Argentina,
219 Korea, The Netherlands, France, Pakistan, Israel, Australia, The United Kingdom, Sweden, Tanzania,
220 Taiwan, Spain, Canada, China, Germany, Brazil, Romania, Korea, Switzerland and Thailand. The
221 average age of included patients was 47,8 years and ranged from 8 to 77 years. All but one study
222 focused primarily on adult participants. Nineteen studies included children. The percentage of female
223 patients included was on average 47,6% and ranged from 10% to 100%. Procedures were diverse and
224 represented gastro-intestinal, cardiac, thoracic, head and neck, gynaecological, obstetrics,
225 trauma/orthopaedics and maxillofacial surgery. All but 17 trials were single centre studies.
226 Fifty-two RCTs including 19,273 participants compared continued postoperative regimens, varying
227 from one postoperative administration to five days of postoperative continuation, to postoperative
228 discontinuation of SAP. Thirty-three RCTs including 5,516 participants compared postoperative SAP
229 regimens of different duration. Of these 33 trials, one RCT with 227 participants compared
230 postoperative continuation of SAP up to 24 hours with a single postoperative dose, 25 RCTs including
231 4,280 participants compared postoperative continuation of SAP for more than 24 hours to postoperative
232 continuation for less than 24 hours six RCTs including 754 participants compared postoperative
233 continuation for more than 48 hours to postoperative continuation for less than 48 hours, and one RCT
234 including 255 participants compared postoperative continuation for more than 72 hours to
235 postoperative continuation for less than 72 hours. Two RCTs had several study arms and provided data
236 on multiple comparisons. Timing of the first preoperative dose of antibiotics was standardized as
237 within 60 minutes of the first incision in 57 RCTs. Forty-six RCTs standardized intraoperative redosing
238 or had procedure durations that did not exceed two halftimes of the antibiotic used. Adherence to
239 current best practice standards, i.e. correct timing prior to incision and repeat of administration during
240 surgery when indicated, was standardized in 34 RCTs. The outcome definition was described as the
241 current CDC definition of SSI in 26 RCTs.²³ The other 57 studies used descriptions ranging from
242 purulent discharge to extensive, field specific descriptions of the clinical manifestation of SSI. All the
243 definitions used are listed in the appendix, p 12. Twenty-four studies reported adverse events and 6
244 studies described resource use.

245 The results of the analyses are presented in Table 1. Meta-analysis of 52 RCTs showed that there was
246 an indication, but not conclusive evidence of a benefit of postoperative continuation of SAP in the
247 prevention of SSI when compared to postoperative discontinuation (RR: 0.89; 95%CI: [0.79-1.00]).
248 Heterogeneity was low ($\tau^2 = 0.001$, chi-squared $P = 0.459$, $I^2 = 0.7\%$). Subgroup analyses and meta-
249 regression indicated that compliance with current best practice standards for SAP modified the
250 association between continuation of postoperative SAP and the incidence of SSI (Subgroup: $P = 0.048$,
251 variance explained: 100%). Only in trials not compliant with current best practice standards (i.e.
252 timing of the first preoperative dose within 60 minutes prior to incision and redosing when procedure
253 duration exceeded two times the half-life of the antibiotic agent was not standardized), continuation of
254 SAP prevented SSI compared with discontinuation (28 RCTs, RR: 0.79; 95%CI: [0.67-0.94], $\tau^2 =$
255 0.019 , $\text{Chi}^2 P = 0.312$, $I^2 = 10.3\%$). When the analysis was restricted to trials that met best practice
256 standards of SAP regarding timing and redosing, this benefit of postoperative SAP continuation was no
257 longer present (24 RCTs, RR: 1.04; 95%CI: [0.85-1.27], $\tau^2 = 0.00$, $\text{Chi}^2 P = 0.784$, $I^2 = 0.0\%$). The
258 forest plot is presented in figure 2; the P value for the subgroup difference was 0.048.

259 Adequate timing or redosing alone did not affect the effect estimate (P for subgroup differences =
260 0.127 and $P = 0.882$ respectively). Exploratory subgroup analysis identified some evidence that
261 postoperative continuation of SAP may reduce the risk of SSI when compared to postoperative
262 discontinuation in maxillofacial surgery and cardiac surgery (P for subgroup differences = 0.024 and P
263 = 0.005 respectively). Only studies that did not adhere to best practice standards were available for
264 both these subgroups. All exploratory subgroup analyses are presented in the appendix, pp 13-14. The
265 remaining meta-analyses, comparing continued postoperative SAP regimens beyond the first
266 preoperative dose of different durations, did not show conclusive evidence of benefit for longer
267 continuation of postoperative antibiotic prophylaxis. Forest plots of the individual meta-analyses are
268 presented in the appendix, pp 15-20.

269 Some 24 studies described possible harms or adverse events related to SAP. Of these, 18 studies
270 reported no adverse events attributable to antibiotic use in both the intervention and control group. Six

271 studies reported more adverse events in the groups with prolonged regimens. One study reported more
272 cases of *Clostridium difficile* infection in the postoperative continuation group. The other studies
273 reported a higher frequency of rash pruritus, erythema, phlebitis, hypotension, gastrointestinal
274 disturbance including nausea and diarrhoea, and unspecified local and systemic side-effects. No study
275 reported on antimicrobial resistance. Due to heterogeneity in the comparisons made, and the outcomes
276 measured, no meta-analysis could be done. Adverse events are listed in the appendix, p 21.
277 Five studies addressed cost effectiveness and reported a cost increase associated with longer antibiotic
278 prophylaxis regimens, in some cases also depending on treatment of side effects and hospitalisation
279 time, which varied from \$36,90 to \$78,95. None of these studies incorporated cost for the emergence of
280 antimicrobial resistance. All five studies were conducted in high income countries. Costs are listed in
281 the appendix, p 22.
282 A summary of the risk of bias evaluations is presented in figure 3 and the full evaluations in the
283 appendix, pp 23-28. Overall the risk of bias was considered serious due to the many unclear
284 assessments, and some assessments of high risk of bias. No funnel plot asymmetry was detected both
285 for the comparisons of continued postoperative regimen with postoperative discontinuation, and
286 postoperative continuation for more than 24 hours with less than 24 hours. There were too few data for
287 the three other comparisons to allow adequate evaluation of the funnel plots. Funnel plots are presented
288 in Figure 4 and the appendix, p 29.
289 An evidence table with full GRADE assessments is presented in table 2. All included studies were
290 RCTs, thus the starting quality of the evidence for each comparison was high. For the main analysis,
291 comparing any postoperative continuation to postoperative discontinuation, the quality of evidence was
292 downgraded to moderate due to serious risk of bias. One subgroup analysis was graded individually
293 because of a strong association with the intervention effect. For the subgroup of studies that reported
294 adherence to current best practice standards the quality of evidence was downgraded to moderate due
295 to serious risk of bias. For the subgroup of studies that did not report adherence to current best practice
296 standards the quality of evidence was downgraded to moderate due to risk of bias. The quality of
297 evidence for the remaining analyses, comparing postoperative regimens of different durations, was
298 downgraded to low in each due to serious risk of bias and imprecision.
299
300

Discussion

Moderate quality evidence from meta-analysis of 52 RCTs and 19,273 participants showed no conclusive evidence for a benefit of postoperative continuation of SAP in reducing the SSI rate as compared to postoperative discontinuation. Similarly, low quality evidence from comparisons of postoperative regimens of different duration showed no conclusive evidence of a benefit of prolonged regimens. Subgroup analysis showed that the effectiveness of postoperatively discontinued SAP depends on appropriateness of SAP practices. When SAP best practices (i.e., timely administration of the first dose and redosing when indicated according to the procedure duration) were applied, moderate quality evidence showed there was no benefit of postoperative SAP continuation in reducing SSI compared to discontinuation of SAP. Moderate quality of evidence showed that postoperative SAP continuation was effective only when these standard conditions of SAP administration were not met. There was some evidence from exploratory analysis that postoperative continuation of SAP may reduce the risk of SSI in maxillofacial surgery and cardiac surgery. Only studies that did not adhere to best practice standards were available for these subgroups. When costs and adverse events were reported, postoperative continuation led to increased cost and more adverse events. These findings are in line with the initial review that supported the strong WHO recommendation against postoperative continuation of SAP and found an odds ratio of 0.89; 95%CI: [0.77-1.03].¹¹ In comparison to this initial WHO meta-analysis, the confidence interval resulting from the present meta-analysis narrowed slightly as more data has accrued, but the point estimate remains unchanged. While there is some evidence of a small benefit in both estimates, the confidence intervals include unity, and do not indicate appreciable benefit with regard to SSI. In particular when SAP best practices were applied, there was no benefit of postoperative SAP continuation overall, or in any specific subspecialty. Antibiotic use itself is associated with important adverse effects in a treatment duration dependent fashion.^{7,30,31} In turn, these adverse effects are associated with a substantial economic burden that adds on to additional acquisition- and administration costs related to postoperative SAP continuation.³²⁻³⁴ Waste that is particularly dreadful in countries with limited resources where this practice is most prevalent.¹⁴ Postoperative SAP continuation is often used to compensate for lack of routine SAP best practices and gaps in other infection prevention measures; this conflicts with the basic principles of antibiotic stewardship and should be changed.³⁵ Most guidelines issued before the WHO SSI prevention guidelines recommended prolongation of SAP to a maximum of 24-48, but were not based on rigorous evaluation of the existing evidence by systematic review.^{4,12} Other systematic reviews that addressed this question were limited to one specific procedure, limiting power and generalizability, and included studies that compare regimens that also differed in dosage or agent in addition to the duration of administration.^{36,37} Indications that postoperative antibiotic prophylaxis may have no added value arose as early as the 1960s.³⁸ Since then, routine postoperative continuation has persisted,³⁹ while concerns on AMR and other adverse effects have risen.^{1,2} Despite the recent guidelines, SAP is still routinely continued up to several days after surgery.¹⁴ New trials emerged after publication of the guidelines, and some of the included data may not be representative for current best practice standards of SAP.⁴ The current findings show that there is no conclusive evidence for a benefit of postoperative continuation of SAP overall. When SAP best practices was followed, post-operative SAP continuation did not yield any additional benefit in reduction of SSI. An important limitation of the current review is that slightly less than half of the included studies standardized current SAP best practices. Any effect identified in the overall estimate could reflect compensation of poor preoperative timing or failure to repeat administration when indicated and overestimate the true effect of SAP continuation. To account for this well-known issue, we conducted pre-specified a subgroup analysis for standardization of current SAP best practices. However, we were limited to aggregate data extracted from publications and did not have individual patient data, thus limiting the granularity of the data and the possibilities for detailed subgroup analysis.⁴⁰ Exploratory subgroup analysis into the effect of postoperative SAP continuation in specific surgical subspecialties was limited by a large number of subgroups, and consequently small numbers per subgroup. These characteristics lead to a high risk of false positive results, and the analysis should be interpreted with caution. Strengths of this study include the broad inclusion, and relevant exclusion criteria. Data from 28 different countries, the adult and paediatric population, and a wide variety of different surgical procedures suggest broad generalizability. Whereas the exclusion of studies on regimens that also differed with regard to dose and agent used, or studies that concerned antibiotic treatment rather than prophylaxis ensured the elimination of important sources of bias. Poor reporting of surgical trials, as previously noted, was an issue in this review as well.⁴¹ This is in part due to the only recent provision of reporting standards.⁴² As a result, a considerable proportion of the risk of bias was unclear, and important information on either timing of the first dose of antibiotics, procedure duration,

361 intraoperative repeat of administration, adverse events or the antibiotic used was frequently missing.
362 We contacted the authors of the concerning studies to request further information, but not all replied to
363 our request. Consequently, we had to assume SAP best practices were not in place in some studies
364 because the required information could not be attained. The subgroup analysis might therefore be
365 contaminated by reporting standards and responsiveness of the corresponding author and should be
366 interpreted with caution. Over half of the included studies used definitions of SSI other than, or not
367 exactly matching, the widely accepted CDC criteria.²³ In most cases this is again attributable to the
368 time of publication. In the 1990s, the CDC definitions were not as widely used as they are now and
369 many alternatives, including preceding versions of the CDC definitions were in use. This challenges
370 interpretation of the clinical importance of the outcomes reported, and comparison of these findings to
371 results of potential future studies. However, an important part of the aim of the present study was to
372 consider all available evidence, and there is evidence that alternative definitional systems provide
373 information similar to that captured in the CDC system.⁴³ Lastly, costs and adverse events were poorly
374 reported if at all, and no meaningful meta-analyses could be conducted to assess these outcomes.
375 Future research to clarify the importance of SAP continuation, if any, should include monitoring of
376 pre-specified adverse events, costs, and standardize preoperative timing and intraoperative repeat of
377 administration.
378 We found no conclusive evidence for a benefit of postoperative continuation of surgical antibiotic
379 prophylaxis as compared to postoperative discontinuation for the reduction of SSI. When SAP best
380 practices are followed, moderate quality of evidence shows that post-operative SAP continuation does
381 not yield any additional benefit in reduction of SSI. These findings support WHO recommendations
382 against this practice. Considering the associated adverse effects, in particular in terms of antimicrobial
383 resistance, there is no basis for this prevalent practice. Increased awareness and education are
384 warranted for both health care professionals and patients, especially by prioritising stewardship efforts
385 among surgeons and anaesthetists and insisting on other infection prevention measures in addition to
386 SAP.

387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413

Contributors

SW and MA designed the study. SW and QJ screened records, extracted data and assessed risk of bias. SW conducted statistical analysis. SW, M, G, B, PE, JS, QJ, MA, analysed and interpreted the data. SW and QJ drafted the manuscript. All authors provided critical conceptual input, interpreted the data analysis, and critically revised the manuscript.

Declaration of interests

S.W. de Jonge, Q.J.J. Boldingh, J.S. Solomkin, B. Allegranzi and M. Egger declare no conflict of interest.
P.E. Dellinger reports personal fees from Destiny Pharma, outside the submitted work
M.A. Boermeester reports grants and other from KCI, grants and other from Johnson&Johnson/Ethicon, grants from New Compliance, grants from Mylan, other from Bard, other from Gore, other from Smith&Nephew, outside the submitted work.
G. Salanti reports other from Biogen, other from Merck, outside the submitted work.

Disclaimer

The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated. WHO takes no responsibility for the information provided or the views expressed in this paper.

Acknowledgments

We thank F. van Etten-Jamaludin for her advice on the search strategy and all the investigators who responded to our requests for data and clarification.

References

1. Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. *Lancet* 2016; **387**(10014): 168-75.
2. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018; **66**(7): e1-e48.
3. Plachouras D, Karki T, Hansen S, et al. Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017. *Euro Surveill* 2018; **23**(46).
4. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. Surgical Infections: Mary Ann Liebert, Inc., publishers; 2013. p. 73-156.
5. Regimbeau JM, Fuks D, Pautrat K, et al. Effect of postoperative antibiotic administration on postoperative infection following cholecystectomy for acute calculous cholecystitis: a randomized clinical trial. *JAMA* 2014; **312**(2): 145-54.
6. Imamura H, Kurokawa Y, Tsujinaka T, et al. Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial. *Lancet Infect Dis* 2012; **12**(5): 381-7.
7. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. *Clin Infect Dis* 2011; **53**(1): 42-8.
8. Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of Duration and Type of Surgical Prophylaxis With Antimicrobial-Associated Adverse Events. *JAMA Surg* 2019; **154**(7): 590-8.
9. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. *Circulation* 2000; **101**(25): 2916-21.
10. Dellit TH, Chan JD, Fulton C, et al. Reduction in Clostridium difficile infections among neurosurgical patients associated with discontinuation of antimicrobial prophylaxis for the duration of external ventricular drain placement. *Infect Control Hosp Epidemiol* 2014; **35**(5): 589-90.
11. WHO. Global Guidelines for the Prevention of Surgical Site Infection. Geneva; 2018.
12. Leaper D, Burman-Roy S, Palanca A, et al. Prevention and treatment of surgical site infection: summary of NICE guidance. *BMJ (Clinical research ed)* 2008; **337**: a1924.
13. Berrios-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. *JAMA Surg* 2017; **152**(8): 784-91.
14. Versporten A, Zarb P, Caniaux I, et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. *Lancet Glob Health* 2018; **6**(6): e619-e29.
15. Fadare JO, Ogunleye O, Iliyasu G, et al. Status of antimicrobial stewardship programmes in Nigerian tertiary healthcare facilities: Findings and implications. *J Glob Antimicrob Resist* 2019; **17**: 132-6.
16. Kalungia AC, Mwambula H, Munkombwe D, et al. Antimicrobial stewardship knowledge and perception among physicians and pharmacists at leading tertiary teaching hospitals in Zambia: implications for future policy and practice. *J Chemother* 2019; **31**(7-8): 378-87.
17. de Santibanes M, Glinka J, Pelegrini P, et al. Extended antibiotic therapy versus placebo after laparoscopic cholecystectomy for mild and moderate acute calculous cholecystitis: A randomized double-blind clinical trial. *Surgery* 2018.
18. Sugawara G, Yokoyama Y, Ebata T, et al. Duration of Antimicrobial Prophylaxis in Patients Undergoing Major Hepatectomy With Extrahepatic Bile Duct Resection: A Randomized Controlled Trial. *Ann Surg* 2018; **267**(1): 142-8.
19. Prospero. <http://www.crd.york.ac.uk/PROSPERO/> (accessed 06-05-2019).
20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ (Clinical research ed)* 2009; **339**: b2535.
21. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. 2011.
22. Jackson JL, Kuriyama A, Anton A, et al. The Accuracy of Google Translate for Abstracting Data From Non-English-Language Trials for Systematic Reviews. *Ann Intern Med* 2019.
23. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. *Am J Infect Control* 1999; **27**(2): 97-132; quiz 3-4; discussion 96.

24. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. *Nucleic acids research* 2008; **36**(Database issue): D901-6.
25. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. *J Clin Epidemiol* 2008; **61**(10): 991-6.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**(3): 177-88.
27. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? *Stat Med* 2002; **21**(11): 1559-73.
28. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis; 2009.
29. Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013.
30. Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of Duration and Type of Surgical Prophylaxis With Antimicrobial-Associated Adverse Events. *JAMA Surg* 2019.
31. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged Antibiotic Prophylaxis After Cardiovascular Surgery and Its Effect on Surgical Site Infections and Antimicrobial Resistance. *Circulation* 2000; **101**: 2916 - 21.
32. OECD. Stemming the Superbug Tide; 2018.
33. Cunha CB. The Pharmacoeconomic Aspects of Antibiotic Stewardship Programs. *Med Clin North Am* 2018; **102**(5): 937-46.
34. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. *Clin Infect Dis* 2012; **55 Suppl 2**: S88-92.
35. Society for Healthcare Epidemiology of A, Infectious Diseases Society of A, Pediatric Infectious Diseases S. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). *Infect Control Hosp Epidemiol* 2012; **33**(4): 322-7.
36. Nelson RL, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. *Cochrane Database Syst Rev* 2014; (5): CD001181.
37. Naimi-Akbar A, Hultin M, Klinge A, Klinge B, Tranaeus S, Lund B. Antibiotic prophylaxis in orthognathic surgery: A complex systematic review. *PLoS One* 2018; **13**(1): e0191161.
38. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. *Surgery* 1961; **50**: 161-8.
39. Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. *Arch Surg* 2005; **140**(2): 174-82.
40. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. *Eval Health Prof* 2002; **25**(1): 76-97.
41. Knobloch K, Gohritz A, Vogt PM. CONSORT and QUOROM statements revisited: standards of reporting of randomized controlled trials in general surgery. *Ann Surg* 2008; **248**(6): 1106-7; discussion 7-8.
42. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ (Clinical research ed)* 2010; **340**: c869.
43. Bruce J, Russell EM, Mollison J, Krukowski ZH. The measurement and monitoring of surgical adverse events. *Health Technol Assess* 2001; **5**(22): 1-194.

Tables

Table 1. Meta-analysis and subgroup analyses of incidence of SSI in Postoperative continuation of SAP vs. postoperative discontinuation of SAP

	No. of studies	SSI in longer regimen	SSI in shorter regimen	Relative risk (95%CI)	τ^2_{MA}	τ^2_{MR}	P-Value for subgroup differences	% of heterogeneity variance explained
Comparison 1: Postoperative continuation of SAP vs postoperative discontinuation of SAP								
<i>Overall summary effect</i>								
Overall	52	492 of 9,726	549 of 9,547	0.89 (0.79, 1.00)	0.001	NA	NA	NA
<i>Timing of first dose specified and within 60 min prior to surgery</i>								
Yes	33	303 of 6,249	314 of 6,151	0.96 (0.82, 1.12)	0.000	0	0.127	100%
No	19	189 of 3,477	236 of 3,396	0.77 (0.61, 0.96)	0.033			
<i>Intraoperative repeat of administration specified when indicated</i>								
Yes	34	265 of 6,126	288 of 5,944	0.89 (0.76, 1.05)	0.000	0.005	0.882	0
No	18	227 of 3,600	262 of 3,603	0.86 (0.70, 1.05)	0.021			
<i>Adherence to current best practice standards of SAP: Timing of first dose specified and within 60 min prior to surgery and intraoperative repeat of administration specified when indicated</i>								
Yes	24	196 of 4,648	186 of 4,552	1.04 (0.85, 1.27)	0.000	0	0.048	100%
No	28	296 of 5,078	364 of 4,995	0.79 (0.67, 0.94)	0.019			
Comparison 2: Postoperative continuation of SAP for multiple postoperative doses <24h vs. postoperative continuation of SAP for one postoperative dose								
Overall	1	44 of 113	39 of 113	0.82 (0.57-1.40)	NA	NA	NA	NA
Comparison 3: Postoperative continuation of SAP > 24h vs postoperative continuation of SAP <= 24h								
Overall	25	170 of 2,038	191 of 2,052	0.93 (0.76, 1.13)	0.000	NA	NA	NA
Comparison 4: Postoperative continuation of SAP > 48h vs postoperative continuation of SAP <= 48h								
Overall	6	42 of 372	31 of 382	1.35 (0.89, 2.03)	0.000	NA	NA	NA
Comparison 5: Postoperative continuation of SAP > 72h vs postoperative continuation of SAP <= 72h								
Overall	1	3 of 125	4 of 130	0.61	NA	NA	NA	NA


				(0.14, 2.63)				
<p>SSI: Surgical site infection, CI: Confidence interval, tau²: Tau-squared (moment estimator), MR: Meta-regression, MA: Meta-analysis, % of heterogeneity variance explained: $\left(\frac{\tau^2_{MA(overall)} - \tau^2_{MR}}{\tau^2_{MA(overall)}}\right)$, <: less than; >: more than; <=: less than or equal to; >=: more than or equal to, SAP: Surgical antibiotic prophylaxis, NA: not available</p>								

Table 2. GRADE assessment of the included evidence

Certainty assessment							№ of patients		Effect		Certain ty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Postoperative continuation	Postoperative discontinuation	Relative (95% CI)	Absolute (95% CI)	○ - ⊕⊕⊕ ⊕
Comparison 1: Postoperative continuation of SAP vs postoperative discontinuation of SAP, Overall summary effect											
52	randomised trials	serious ^a	not serious	not serious	not serious (OIS: 3629 per arm)	none	492/9726 (5.1%)	549/9547 (5.8%)	RR 0.89 (0.79 to 1.00)	6 fewer per 1,000 (from 12 fewer to 0 fewer)	⊕⊕⊕ ○ MODE RATE
Comparison 1, subgroup: Postoperative continuation of SAP vs postoperative discontinuation of SAP, Adherence to current best practice standards of SAP											
24	randomised trials	serious ^a	not serious	not serious	not serious (OIS: 5185 per arm)	none	196/4648 (4.2%)	186/4552 (4.1%)	RR 1.04 (0.85 to 1.27)	2 more per 1,000 (from 6 fewer to 11 more)	⊕⊕⊕ ○ MODE RATE
Comparison 1, subgroup: Postoperative continuation of SAP vs postoperative discontinuation of SAP, No adherence to current best practice standards of SAP											
28	randomised trials	serious ^a	not serious	not serious	not serious (OIS: 2823 per arm)	none	296/5078 (5.8%)	364/4995 (7.3%)	RR 0.79 (0.67 to 0.94)	15 fewer per 1,000 (from 24 fewer to 4 fewer)	⊕⊕⊕ ○ MODE RATE
Comparison 2: Postoperative continuation of SAP for multiple postoperative doses <24h vs. postoperative continuation of SAP for one postoperative dose											
1	randomised trials	serious ^a	not serious	not serious	serious ^{b,c} (OIS: 444 per arm)	none	44/113 (38.9%)	39/113 (34.5%)	RR 0.82 (0.57 to 1.40)	62 fewer per 1,000 (from 148 fewer to 138 more)	⊕⊕○ ○ LOW
Comparison 3: Postoperative continuation of SAP > 24h vs postoperative continuation of SAP ≤ 24h											
25	randomised trials	serious ^a	not serious	not serious	serious ^b (OIS: 2168 per arm)	none	170/2038 (8.3%)	191/2052 (9.3%)	RR 0.93 (0.76 to 1.13)	7 fewer per 1,000 (from 22 fewer to 12 fewer)	⊕⊕○ ○ LOW


										more)	
Comparison 4: Postoperative continuation of SAP > 48h vs postoperative continuation of SAP ≤ 48h											
6	randomised trials	serious ^a	not serious	not serious	serious ^b (OIS: 2515 per arm)	none	42/372 (11.3%)	31/382 (8.1%)	RR 1.35 (0.89 to 2.03)	28 more per 1,000 (from 9 fewer to 84 more)	⊕⊕○ ○ LOW
Comparison 5: Postoperative continuation of SAP > 72h vs postoperative continuation of SAP ≤ 72h											
1	randomised trials	serious ^a	not serious	not serious	serious ^{b,c} (OIS: 6950)	none	3/125 (2.4%)	4/130 (3.1%)	RR 0.61 (0.14 to 2.63)	12 fewer per 1,000 (from 26 fewer to 50 more)	⊕⊕○ ○ LOW
<p>a: Risk of selection bias, performance bias, detection bias, attrition bias and reporting bias; b: Optimal information was not obtained; c: Optimal information was obtained, but confidence interval included considerable benefit of SAP continuation (> RRR 0.25); CI: Confidence interval; RR: Risk ratio; SAP: Surgical antibiotic prophylaxis; OIS: Optimal information size</p>											

Figure 1. PRISMA flowchart of the study selection process




The figure provides a visualisation of the study selection. *: Reasons for exclusion after full-text assessment are shown in the appendix, pp3-4; †: Two RCTs had several study arms and provided data on multiple comparisons; RCT: Randomized controlled trial; >: More than; <: Less than.

Figure 2. Forest plot: Postoperative continuation vs. postoperative discontinuation of surgical antibiotic prophylaxis. Subgroup analysis: Adherence to current best practice standards of SAP




Forest plot of meta-analysis, comparing the effect of postoperatively continued surgical antibiotic prophylaxis with postoperative discontinuation - using the same agent and the same dose per administration - on the risk of surgical-site infection (SSI). The forest plot is sub grouped by adherence to current best practice standards of SAP for perioperative surgical antibiotic prophylaxis (1 meaning adherent, 0 meaning not adherent). A DerSimonian & Laird random-effects model was used. Relative risk is shown with 95% confidence intervals. Solid diamonds and horizontal lines represent point estimates and corresponding 95% confidence intervals of the individual studies respectively. The transparent diamond represents the overall estimate and 95% confidence interval.

Figure 3. Risk of bias graph of the included studies



The figure illustrates the proportion of studies with each of the judgments ('Low risk', 'High risk', 'Unclear risk' of bias) for each of the criteria for risk of bias assessment; random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias.

Figure 4. Funnel plot: Postoperative continuation of surgical antibiotic prophylaxis vs. postoperative discontinuation of surgical antibiotic prophylaxis.



The figure illustrates the distribution of effect estimates of the different studies (x-axis) against their precision (y-axis). Asymmetry across the vertical midline, representing the overall effect estimate of the meta-analysis, indicates publication bias. Both funnel plots show a symmetrical distribution and no indication of publication bias.